EUVIMEDEUVIMED entdecken
Crossref

Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease

Tal Marshanski, Eliana Fanous, Noa Tal, Tsachi T Perets, Manar Matar, Yael Weintraub, Raanan Shamir, Dror S Shouval iD

Journal of Pediatric Gastroenterology and Nutrition · 2024

DOI: 10.1002/jpn3.12307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, 2024. Verfasst von Tal Marshanski und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab, Gastrointestinal Agents, Remission Induction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: None.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Multiple studies in patients with Crohn's disease (CD) treated with anti‐tumor necrosis factor alpha agents have shown that proactive therapeutic drug monitoring (TDM) during the maintenance phase leads to improved outcomes. We aimed to assess whether accelerated (IFX) administration during induction resulted in improved outcomes.

Methods

This retrospective study included CD patients aged 5–17.9 years that were treated with IFX. We compared outcomes of patients treated during induction with 5–8 mg/kg dosing at Weeks 0, 2, 6, and 14 (Group 1), versus accelerated dosing (≥8 mg/kg and/or >4 infusions until Week 14, Group 2) of IFX. Primary outcome was steroid‐free clinical remission by Week 52.

Results

Sixty‐eight patients were included, of whom seven discontinued IFX before Week 14, due to infusion reactions, immunogenic failure, or primary nonresponse. Comparison of Group 1 ( n = 25) and Group 2 ( n = 36) showed similar clinical characteristics, as well as inflammatory markers, at IFX initiation. Despite receiving significantly more IFX, and reaching a higher trough level by Week 14 (10.3 ± 1.2 vs. 3.3 ± 0.7, p < 0.001), the median Pediatric Crohn's disease Activity Index (PCDAI) was slightly higher in Group 2 versus Group 1 (14 [5–20] vs. 5 [0–15], p = 0.02). However, at Weeks 26 and 52 the PCDAI and inflammatory markers were comparable between the groups. Moreover, about 70% in both groups achieved the desirable trough IFX levels by Week 52.

Conclusion

Accelerated IFX dosing during induction did not result in improved outcomes up to 12 months follow‐up. Prospective studies are required to determine the exact timing in which proactive TDM should be applied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabGastrointestinal AgentsRemission InductionHumansChildRetrospective StudiesAdolescentMaleFemaleChild, PreschoolTreatment OutcomeDrug MonitoringDose-Response Relationship, DrugDrug Administration Schedule

Stichwörter der Autor:innen

Crohn's diseaseIBDinfliximabproactive TDMtherapuetic drug monitoring

Substanzen

InfliximabGastrointestinal Agents

Autor:innen und Institutionen

  • Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Gastroenterology Laboratory, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel.
  • Department of Digital Medical Technologies, Holon Institute of Technology, Holon, Israel.

ORCID-Profile: Dror S Shouval

Förderung

  • None

Zitieren

APA

Marshanski, T., Fanous, E., Tal, N., Perets, T. T., Matar, M., Weintraub, Y., Shamir, R., & Shouval, D. S. (2024). Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. https://doi.org/10.1002/jpn3.12307

Vancouver

Marshanski T, Fanous E, Tal N, Perets TT, Matar M, Weintraub Y, et al. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. 2024. doi:10.1002/jpn3.12307

BibTeX
@article{Marshanski2024,
  author = {Marshanski, Tal and Fanous, Eliana and Tal, Noa and Perets, Tsachi T and Matar, Manar and Weintraub, Yael and Shamir, Raanan and Shouval, Dror S},
  title = {Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  doi = {10.1002/jpn3.12307}
}
Kostenlos starten →